XY028-140-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEXY028-140Cat.No.:HY-138946CASNo.:2229974-83-6分?式:C??H??N??O?分?量:760.8作?靶點(diǎn):CDK;PROTACs作?通路:CellCycle/DNADamage;PROTAC儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:5.56mg/mL(7.31mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.3144mL6.5720mL13.1441mL5mM0.2629mL1.3144mL2.6288mL10mM---------請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:0.56mg/mL(0.74mM);Suspendedsolution;Needultrasonic1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性XY028-140由Cereblon配體和CDK配體相連的PROTAC。XY028-140抑制癌細(xì)胞中的CDK4/6表達(dá)和CDK4/6活性。IC50&TargetCDK4CDK6Cereblon體外研究A375melanomaandT47Dbreastcancercellsaretreatedwith0.3or1μΜXY028-140for24hours.XY028-140inhibitsbothCDK4/6expressionandCDK4/6activity[1].T47Dbreastcancercellsaretreatedwith0.03,0.1,0.3,1,or3μΜXY028-140for11days.XY028-140inhibitscancercellproliferationinbreastcancercells[1].REFERENCES[1].JianJin,etal.Compositionsandmethodsfortreatingcdk4/6-mediatedcancer.WO2018106870A1.[2].XueweiWu,etal.DistinctCDK6complexesdeterminetumorcellresponsetoCDK4/6inhibitorsanddegraders.NatCancer2,429-443(2021).McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;